Neuraminidase, also known as sialidase, is an important glycoprotein in influenza viruses that cleaves sialic acid from the infected cell surface and releases virus progeny \[[@B1]\]. It plays a major role in viral proliferation and infecting other cells \[[@B2]\]. Thus, neuraminidase is an attractive therapeutic drug target for the treatment of influenza. Currently, neuraminidase inhibitors such as zanamivir (Relenza; Glaxo Wellcome Inc., Research Triangle Park, NC, USA) and oseltamivir (Tamiflu; Roche, Nutley, NJ, USA) are used for the treatment of influenza. However, several problems are associated with these drugs, including a high level of drug resistance and diverse side effects such as vomiting and nausea \[[@B3][@B4]\]. Therefore, next-generation neuraminidase inhibitors are urgently needed.

Mushrooms are both a nutritional food source and a traditional medicine. They produce various classes of bioactive secondary metabolites with unique chemical structures \[[@B5][@B6]\]. In previous studies, we reported the isolation of neuraminidase inhibitors from *Phellinus baumii* and *P. linteus* and their biological properties \[[@B7][@B8][@B9]\]. As part of an ongoing effort to identify neuraminidase inhibitors from medicinal fungi, we found that the methanolic extract of fruiting bodies of *P. igniarius* exhibited significant H3N2 neuraminidase inhibitory activity. *Phellinus igniarius*, belonging to the family Hymenochaetaceae, has been used to treat fester, abdominalgia, and bloody gonorrhea in traditional medicine in Korea, Japan, and China and has been reported to possess anti-oxidative, anti-proliferative, anti-metastatic, and antiinfluenza activities \[[@B10][@B11][@B12]\]. In this study, we describe the isolation, structure determination, and biological properties of neuraminidase inhibitors from the methanolic extract of *P. igniarius*.

Isolation of neuraminidase inhibitors.
======================================

In order to isolate neuraminidase inhibitors, the fruiting bodies of *P. igniarius* were extracted using methanol for 2 days at room temperature. The methanolic extract was concentrated under reduced pressure, and the resultant residue was partitioned twice with ethyl acetate. The ethyl acetate-soluble layer was subjected to Sephadex LH-20 column chromatography (Pharmacia, Uppsala, Sweden) eluted with methanol to yield two active fractions. One active fraction was further purified by Sephadex LH-20 column chromatography eluted with 70% aqueous methanol to provide compound **1**. The other fraction was subjected to Sephadex LH-20 column chromatography with 70% aqueous methanol as the eluting solvent to yield compound **2**.

Structure determination of neuraminidase inhibitors.
====================================================

The chemical structures of compounds **1** and **2** were determined via electrospray ionization (ESI)-mass and proton nuclear magnetic resonance (^1^H NMR) spectrum measurements. The molecular weight of compound **1** was 474 on ESI-mass measurement, where it exhibited a quasimolecular ion peak at *m/z* 475 \[M+H\]^+^. The ^1^H NMR spectrum of **1** in DMSO-*d*~6~ demonstrated seven methine protons at δ 8.24, 7.85, 7.47, 6.97, 6.61, 6.15, and 6.09 and one methyl signal at δ 2.50. Based on literature review, compound **1** was identified as phelligridin E; the molecular weight and ^1^H chemical shift values were in good agreement with those previously reported for phelligridin E \[[@B13]\].

The chemical structure of compound **2** was also determined via ESI-mass and ^1^H NMR spectrum measurements. The molecular weight of compound **2** was 594 on ESI-mass measurement, and it demonstrated a quasi-molecular ion peak at *m/z* 595 \[M+H\]^+^. The ^1^H NMR spectrum of compound **2** in DMSO-*d*~6~ showed three aromatic methine signals assignable to a 1,2,4-trisubstituted benzene moiety at δ 7.17 (d, *J* = 2.1 Hz), 7.10 (dd, *J* = 8.2, 2.1 Hz), and 6.79 (d, *J* = 8.2 Hz), two olefinic methine peaks attributable to a *trans*-1,2-disubstituted double bond at δ 7.54 (d, *J* = 16.2 Hz) and 7.10 (d, *J* = 16.2 Hz), and seven methine singlets at δ 8.28, 7.86, 7.48, 7.01, 6.64, 6.25, and 6.02. These spectral data were consistent with those of phelligridin G previously reported in the literature \[[@B14]\]. Therefore, compounds **1** and **2** were identified as phelligridin E and phelligridin G, respectively, as shown in [Fig. 1](#F1){ref-type="fig"}.

Neuraminidase inhibition activity.
==================================

The inhibitory activity of compounds **1** and **2** against neuraminidases from recombinant rvH1N1, H3N2, and H5N1 influenza viruses was evaluated. Neuraminidase inhibition assay was performed in 96-well plates as previously described \[[@B15]\], with some modifications. Briefly, the substrate, 50 µL of 0.2 mM MUNANA (2-(4-methylumbelliferyl)-α-D-*N*-acetylneuraminic acid sodium salt; Sigma, St. Louis, MO, USA), was mixed with 90 µL of 50mM Tris buffer (containing 200 mM NaCl, 5 mM CaCl~2~, pH 7.5) at room temperature. Ten microliters of the sample and 50 µL of H1N1 neuraminidase (50 ng/mL) were added to each well. The mixture was then recorded at the excitation and emission wavelengths of 365 nm and 445 nm, respectively, using a POLAR OPTIMA (BMG LABTECH, Ortenberg, Germany). In the case of H3N2 and H5N1 neuraminidases, 25 mM MES buffer (containing 500 mM NaCl, 5 mM CaCl~2~, pH 6.5) and 50 mM MES buffer (containing 500 mM NaCl, 5 mM CaCl~2~, pH 6.5) were used, respectively, and H5N1 required an activation period of 24 hr at 37℃ before assay. The other methods were the same as used for H1N1 neuraminidase. A neuraminidase inhibitor, zanamivir (Relenza) was used as a positive control. Compounds **1** and **2** showed H3N2 neuraminidase inhibition activity with an IC~50~ value of 6.7 µM, respectively, in a dose-dependent manner. Inhibitory activity of compounds **1** and **2** against H1N1 and H5N1 neuramanidases were also evaluated. These compounds significantly inhibited the H1N1 and H5N1 neuramanidases with IC~50~ values in the range of 8.0\~1.0 µM in a dose-dependent manner ([Table 1](#T1){ref-type="table"}).

We investigated the inhibition type of compounds **1** and **2** using kinetic parameters. To study the mode of inhibition, Dixon plots were used to distinguish the mechanism of neuraminidase enzyme action and to confirm the inhibition constant (*K*~i~). The data were measured using Sigmaplot ver. 1.3 (Systat, Chicago, IL, USA). Compounds **1** and **2** displayed noncompetitive inhibitory activity, as indicated by a decrease in Vmax while Km remained stable at increasing inhibitor concentrations. The inhibition constant (*K*~i~) values of compounds **1** and **2** were 7.1 ± 0.3 and 6.9 ± 0.3, respectively ([Fig. 2](#F2){ref-type="fig"}).
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###### Neuraminidase inhibitory activity of compounds **1** and **2**
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NT, not tested.
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